Risks of modifying flu strains to become highly transmissible in humans outweigh benefits

NewsGuard 100/100 Score

In this Journal Sentinel Online opinion piece, Thomas Inglesby, chief executive officer and director of the Center for Biosecurity of UPMC in Baltimore; Anita Cicero, chief operating officer and deputy director of the center; and D.A. Henderson, a distinguished scholar at the center, comment on a recent announcement by scientists that they have genetically modified a strain of H5N1 bird flu that is "capable of spreading through the air between ferrets that were physically separated from each other," indicating "it would be readily transmissible by air between humans." They write, "We believe the benefits of [purposefully engineer(ing) avian flu strains to become highly transmissible in humans] do not outweigh the risks."

"[T]he Center for Biosecurity of UPMC has publicly argued for the importance of [research in high-containment labs using dangerous pathogens, including H5N1,] to develop diagnostics, medicines and vaccines for the most threatening infectious diseases," but "research and development for those purposes does not require engineering lethal viruses to make them more transmissible between humans," they continue. "We need new approaches for the rapid development of large quantities of medicines or vaccines to protect us against new emerging viruses. But engineering highly transmissible strains of avian flu is not the way to get us there," they conclude (1/14).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop promising recombinant flu vaccine using nanoliposome technology